Stop Writing ‘Routine Labs.’ Every Lab Line Needs Its Own Coverage Citation

THE BILLING GRID
A weekly column on research billing and coverage analysis, by Krishma Shah

A billing compliance officer at a mid-sized academic medical center once pulled a coverage analysis for a Phase II oncology trial and found a single line in the lab section: Routine labs, SOC. Twelve procedures. One designation. Zero citations. That MCA (medical coverage analysis, the document that assigns each protocol procedure a payer designation and legal basis) would not survive a contractor audit, and it would not survive an OIG review either. The site had been billing Medicare for those procedures for eight months.

This is not a hypothetical failure mode. It is the most common structural weakness in site-level MCAs, and it persists because “routine” feels like a complete thought. It is not. Routine describes clinical familiarity. It does not describe Medicare coverage. Those are different questions, and conflating them is where research billing liability begins.

The Unit of Defense Is the Cell, Not the Category

A properly constructed MCA assigns a designation, SOC (standard of care, billable to Medicare or insurer when the trial qualifies), RES (research-paid, sponsor cost), or NB/INV (non-billable or invoiceable per the site budget), to each individual procedure at each individual visit. The defensible unit is the visit-grid cell: the same CBC can be SOC at the baseline visit and RES at an unscheduled safety visit driven entirely by protocol, depending on clinical context and what the protocol requires versus what would occur in routine oncology care outside the trial.

When a lab section says “routine labs, SOC” across all visits, the MCA has collapsed dozens of cells into one assertion. An auditor working from the protocol visit schedule and the site’s charge master will reconstruct those cells individually. If your MCA does not show the citation that justifies SOC for each one, the site cannot demonstrate that the billing decision was made deliberately. That is the evidentiary gap that turns a documentation problem into a compliance problem.

The Lab NCD Family Is Specific and Searchable

Medicare coverage for laboratory procedures is governed by a family of National Coverage Determinations (NCDs, the national-level Medicare coverage rules issued by CMS). These are not catch-all authorizations. Each NCD specifies which diagnoses or clinical conditions support coverage, what frequency is covered, and in some cases what clinical setting applies.

For a complete blood count, the operative citation is NCD 190.15. It does not cover a CBC because a protocol schedules one. It covers a CBC when the clinical indication aligns with the conditions the NCD enumerates. That distinction matters at every visit. A baseline CBC in an oncology trial where the patient has a qualifying diagnosis and the CBC is not required solely by the protocol may be SOC under NCD 190.15. A CBC scheduled at week 16 only because the protocol requires it for safety monitoring is a different analysis, and the MCA needs to show that analysis was done.

The same logic applies across the lab panel. Comprehensive metabolic panels, liver function tests, coagulation studies, urinalyses, lipid panels, and tumor markers each have their own NCD or LCD (local coverage determination, the regional-level Medicare coverage rule issued by a Medicare Administrative Contractor) that governs when billing is appropriate. Writing a single line for “chemistry panel, SOC” when that panel contains a half-dozen individually covered tests is not a shortcut. It is an undocumented billing decision waiting to be questioned.

A Worked Example: Oncology Trial, Baseline Visit

Consider a protocol that schedules the following at the baseline visit: CBC with differential, comprehensive metabolic panel (CMP), LDH, and a CA-125 tumor marker. The trial qualifies under NCD 310.1 (the national coverage determination for routine costs in qualifying clinical trials, which applies to trials under IND with therapeutic intent and Medicare-benefit-category items). The site is treating patients with ovarian cancer.

A citation-level MCA for that single visit would work through each test independently. The CBC gets NCD 190.15 and a notation of the qualifying diagnosis. The CMP is analyzed under the applicable LCD for the MAC jurisdiction, because metabolic panels do not have a single national NCD the way CBCs do, coverage is regional, and the analyst needs to pull the right contractor document. LDH in an oncology context is assessed against the relevant LCD for tumor marker testing. CA-125 has specific coverage criteria tied to diagnosis and treatment context that require explicit documentation.

Four tests. Four citations or citation attempts. If one of those tests does not meet SOC criteria at the baseline visit, perhaps the protocol is collecting LDH for pharmacodynamic reasons that have no correlate in standard oncology practice for this indication, it goes to RES, sponsor-paid, and the budget pass later reconciles that against the sponsor’s grant. That is the analysis. It takes longer than writing “routine labs, SOC.” It is also the only version that holds up.

Why Summary-Level MCAs Fail Audits That Citation-Level MCAs Survive

The Rush University Medical Center case from 2005 is the reference point that billing compliance officers in academic medicine still cite. The core fact pattern was straightforward: procedures that should have been charged to the research sponsor were billed to Medicare. The MCA structure at the visit level is the primary control that prevents that error from happening systematically, because it forces the coverage question to be answered before the patient is enrolled, not after the claim is filed.

When a contractor auditor reviews research billing, they are not accepting the MCA’s conclusions on faith. They are checking whether the MCA’s stated basis is sufficient to support the designation. A summary-level MCA that says “routine labs, SOC” gives the auditor nothing to evaluate. A citation-level MCA that says “CBC, NCD 190.15, qualifying diagnosis documented, SOC at baseline and cycle 1 day 1 visits; RES at unscheduled safety visits” gives the auditor a position to either accept or rebut. That is the difference between a defensible document and an absent one.

Sites that adopt citation-level MCA construction also find a secondary benefit: the budget reconciliation pass is faster. When the invoiceable section of the MCA is built from the same cell-level analysis, the finance team can price research-paid items against the charge master with the designations already resolved. The budget does not have to re-litigate coverage questions that the MCA should have answered at feasibility.

What to Fix Before the Next Protocol Lands

If your current MCA template has a lab section that accepts free-text category entries without requiring a citation field, the template is the problem. The fix is structural: every lab row in the procedure grid needs a citation column that cannot be left blank. Acceptable entries are an NCD number, an LCD identifier with the MAC jurisdiction, or an explicit RES or NB designation with the rationale. “Routine” is not an entry. It is a flag that the analysis was not done.

The MCA sits on the site-activation critical path alongside the contract and the IRB. Getting it right at feasibility, before the budget pass, before first-patient-in, is the only sequence that protects the site. Fixing it after a claim is filed is compliance remediation. Fixing it before is operations.